Literature DB >> 18261732

Prospective association of vascular endothelial growth factor-A (VEGF-A) with coronary heart disease mortality in southeastern New England.

Charles B Eaton1, Robert Gramling, Donna R Parker, Mary B Roberts, Bing Lu, Paul M Ridker.   

Abstract

BACKGROUND: Autopsy data suggest that plaque neovascularization may be associated with coronary heart disease (CHD) death. Since vascular endothelial growth factor-A (VEGF-A) is upregulated in angiogenesis and therefore neovascularization, we hypothesized that individuals with elevated levels of VEGF-A at baseline would be a greater risk of dying of CHD compared to those with lower levels over time.
METHODS: We measured VEGF-A levels in 46 CHD death cases and a 14% random sample of 2321 community participants who were free of self-reported CHD at baseline. Traditional CHD risk factors such as age, gender, family history of CHD, cigarette smoking, hypertension, total cholesterol/HDL ratio, diabetes mellitus, were also evaluated at baseline. Mortality follow-up was determined through linkage of baseline data with the National Death Index.
RESULTS: During a median of 13 years of follow-up, 46 subjects died of coronary heart disease. Mean VEGF-A levels were significantly higher in the CHD death cases than among the random population sample (400 pg/ml vs. 303 pg/ml, p=0.0004). In proportional hazards models adjusting for traditional risk factors, the hazard ratios (95%CI) for CHD death associated with increasing tertiles of VEGF-A were 1.0 (referent), 2.12 (0.74, 6.10), and 3.85 (1.37, 10.78), respectively (P(test for trend)=0.008).
CONCLUSION: In this population-based prospective, case-cohort study, baseline levels of VEGF-A showed a significant independent association with the risk of CHD death.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18261732     DOI: 10.1016/j.atherosclerosis.2007.12.027

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  10 in total

1.  Social isolation, C-reactive protein, and coronary heart disease mortality among community-dwelling adults.

Authors:  Kathi L Heffner; Molly E Waring; Mary B Roberts; Charles B Eaton; Robert Gramling
Journal:  Soc Sci Med       Date:  2011-03-30       Impact factor: 4.634

2.  Circulating angiopoietins-1 and -2, angiopoietin receptor Tie-2 and vascular endothelial growth factor-A as biomarkers of acute myocardial infarction: a prospective nested case-control study.

Authors:  Carlos Iribarren; Bruce H Phelps; Jeanne A Darbinian; Edward R McCluskey; Charles P Quesenberry; Evangelos Hytopoulos; Joseph H Vogelman; Norman Orentreich
Journal:  BMC Cardiovasc Disord       Date:  2011-06-14       Impact factor: 2.298

3.  Is the association between optimistic cardiovascular risk perceptions and lower rates of cardiovascular disease mortality explained by biomarkers of systemic inflammation or endothelial function? A case-cohort study.

Authors:  Robert Gramling; Kathi L Heffner; William Mp Klein; Laura E Zajac; Mary Roberts; Charles B Eaton
Journal:  Biopsychosoc Med       Date:  2010-09-21

4.  A common variant highly associated with plasma VEGFA levels also contributes to the variation of both LDL-C and HDL-C.

Authors:  Maria G Stathopoulou; Amélie Bonnefond; Ndeye Coumba Ndiaye; Mohsen Azimi-Nezhad; Said El Shamieh; Abdelsalam Saleh; Marc Rancier; Gerard Siest; John Lamont; Peter Fitzgerald; Sophie Visvikis-Siest
Journal:  J Lipid Res       Date:  2012-12-02       Impact factor: 5.922

5.  Residential black carbon exposure and circulating markers of systemic inflammation in elderly males: the normative aging study.

Authors:  Shona C Fang; Amar J Mehta; Stacey E Alexeeff; Alexandros Gryparis; Brent Coull; Pantel Vokonas; David C Christiani; Joel Schwartz
Journal:  Environ Health Perspect       Date:  2012-02-15       Impact factor: 9.031

6.  Prognostic value of VEGF in patients submitted to percutaneous coronary intervention.

Authors:  Catarina Ramos; Patrícia Napoleão; Mafalda Selas; Cláudia Freixo; Ana Maria Viegas Crespo; Miguel Mota Carmo; Rui Cruz Ferreira; Teresa Pinheiro
Journal:  Dis Markers       Date:  2014-07-07       Impact factor: 3.434

7.  Association of genetic polymorphisms in vascular endothelial growth factor with susceptibility to coronary artery disease: a meta-analysis.

Authors:  Wen-Qi Ma; Ying Wang; Xi-Qiong Han; Yi Zhu; Nai-Feng Liu
Journal:  BMC Med Genet       Date:  2018-07-04       Impact factor: 2.103

8.  Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet.

Authors:  Kouichi Miura; Hirohide Ohnishi; Naoki Morimoto; Shinichiro Minami; Mitsuaki Ishioka; Shunji Watanabe; Mamiko Tsukui; Yoshinari Takaoka; Hiroaki Nomoto; Norio Isoda; Hironori Yamamoto
Journal:  Cancer Sci       Date:  2019-01-09       Impact factor: 6.716

9.  Association between SNPs of Circulating Vascular Endothelial Growth Factor Levels, Hypercholesterolemia and Metabolic Syndrome.

Authors:  Ali Salami; Said El Shamieh
Journal:  Medicina (Kaunas)       Date:  2019-08-11       Impact factor: 2.430

10.  Deciphering the genetic and modular connections between coronary heart disease, idiopathic pulmonary arterial hypertension and pulmonary heart disease.

Authors:  Ye Yuan; Yingying Zhang; Xiaoxu Zhang; Yanan Yu; Bing Li; Pengqian Wang; Haixia Li; Yijun Zhao; Chunti Shen; Zhong Wang
Journal:  Mol Med Rep       Date:  2016-05-18       Impact factor: 2.952

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.